280 related articles for article (PubMed ID: 23446880)
21. Development and validation of the comprehensive assessment scale for chemotherapy-induced peripheral neuropathy in survivors of cancer.
Kanda K; Fujimoto K; Mochizuki R; Ishida K; Lee B
BMC Cancer; 2019 Sep; 19(1):904. PubMed ID: 31506070
[TBL] [Abstract][Full Text] [Related]
22. Chemotherapy-induced peripheral neuropathy (CIPN) in breast cancer survivors: a comparison of patient-reported outcomes and quantitative sensory testing.
Zhi WI; Chen P; Kwon A; Chen C; Harte SE; Piulson L; Li S; Patil S; Mao JJ; Bao T
Breast Cancer Res Treat; 2019 Dec; 178(3):587-595. PubMed ID: 31456070
[TBL] [Abstract][Full Text] [Related]
23. Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy.
Molassiotis A; Cheng HL; Lopez V; Au JSK; Chan A; Bandla A; Leung KT; Li YC; Wong KH; Suen LKP; Chan CW; Yorke J; Farrell C; Sundar R
BMC Cancer; 2019 Feb; 19(1):132. PubMed ID: 30736741
[TBL] [Abstract][Full Text] [Related]
24. The association of chemotherapy-induced peripheral neuropathy with reduced executive function in chemotherapy-treated cancer survivors: A cross-sectional study.
McNeish BL; Dittus K; Mossburg J; Krant N; Steinharter JA; Feb K; Cote H; Hehir MK; Reynolds R; Redfern MS; Rosano C; Richardson JK; Kolb N
J Geriatr Oncol; 2024 May; 15(4):101765. PubMed ID: 38581957
[TBL] [Abstract][Full Text] [Related]
25. Longitudinal validation and comparison of the Chinese version of the European Organization for Research and Treatment of Cancer Quality of Life-Chemotherapy-Induced Peripheral Neuropathy Questionnaire (EORTC QLQ-CIPN20) and the Functional Assessment of Cancer-Gynecologic Oncology Group-Neurotoxicity subscale (FACT/GOG-Ntx).
Cheng HL; Molassiotis A
Asia Pac J Clin Oncol; 2019 Feb; 15(1):56-62. PubMed ID: 29873180
[TBL] [Abstract][Full Text] [Related]
26. A longitudinal examination of associations between age and chemotherapy-induced peripheral neuropathy in patients with gynecologic cancer.
Bulls HW; Hoogland AI; Kennedy B; James BW; Arboleda BL; Apte S; Chon HS; Small BJ; Gonzalez BD; Jim HSL
Gynecol Oncol; 2019 Feb; 152(2):310-315. PubMed ID: 30558975
[TBL] [Abstract][Full Text] [Related]
27. Reference data of the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-CIPN20 Questionnaire in the general Dutch population.
Mols F; van de Poll-Franse LV; Vreugdenhil G; Beijers AJ; Kieffer JM; Aaronson NK; Husson O
Eur J Cancer; 2016 Dec; 69():28-38. PubMed ID: 27814471
[TBL] [Abstract][Full Text] [Related]
28. Exploring assessment of balance using virtual reality in patients at risk of chemotherapy-induced peripheral neuropathy.
Teng C; Chiarovano E; Tighe D; Bui KT; Venkatesha ; Blinman PL; MacDougall HG; Vardy JL
Intern Med J; 2023 Aug; 53(8):1356-1365. PubMed ID: 35762188
[TBL] [Abstract][Full Text] [Related]
29. Chemotherapy-Induced Peripheral Neuropathy: Association With Increased Risk of Falls and Injuries.
Autissier E
Clin J Oncol Nurs; 2019 Aug; 23(4):405-410. PubMed ID: 31322611
[TBL] [Abstract][Full Text] [Related]
30. It's never too late - balance and endurance training improves functional performance, quality of life, and alleviates neuropathic symptoms in cancer survivors suffering from chemotherapy-induced peripheral neuropathy: results of a randomized controlled trial.
Kneis S; Wehrle A; Müller J; Maurer C; Ihorst G; Gollhofer A; Bertz H
BMC Cancer; 2019 May; 19(1):414. PubMed ID: 31046719
[TBL] [Abstract][Full Text] [Related]
31. Exercise-based rehabilitation for cancer survivors with chemotherapy-induced peripheral neuropathy.
McCrary JM; Goldstein D; Sandler CX; Barry BK; Marthick M; Timmins HC; Li T; Horvath L; Grimison P; Park SB
Support Care Cancer; 2019 Oct; 27(10):3849-3857. PubMed ID: 30756229
[TBL] [Abstract][Full Text] [Related]
32. Executive function is associated with balance and falls in older cancer survivors treated with chemotherapy: A cross-sectional study.
McNeish BL; Dittus K; Mossburg J; Krant N; Steinharter JA; Feb K; Cote H; Hehir MK; Reynolds R; Redfern MS; Rosano C; Richardson JK; Kolb N
J Geriatr Oncol; 2023 Nov; 14(8):101637. PubMed ID: 37776612
[TBL] [Abstract][Full Text] [Related]
33. Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial.
Kleckner IR; Kamen C; Gewandter JS; Mohile NA; Heckler CE; Culakova E; Fung C; Janelsins MC; Asare M; Lin PJ; Reddy PS; Giguere J; Berenberg J; Kesler SR; Mustian KM
Support Care Cancer; 2018 Apr; 26(4):1019-1028. PubMed ID: 29243164
[TBL] [Abstract][Full Text] [Related]
34. Interactive Sensor-Based Balance Training in Older Cancer Patients with Chemotherapy-Induced Peripheral Neuropathy: A Randomized Controlled Trial.
Schwenk M; Grewal GS; Holloway D; Muchna A; Garland L; Najafi B
Gerontology; 2016; 62(5):553-63. PubMed ID: 26678611
[TBL] [Abstract][Full Text] [Related]
35. The prevalence and pattern of chemotherapy-induced peripheral neuropathy among women with breast cancer receiving care in a large community oncology practice.
Simon NB; Danso MA; Alberico TA; Basch E; Bennett AV
Qual Life Res; 2017 Oct; 26(10):2763-2772. PubMed ID: 28664460
[TBL] [Abstract][Full Text] [Related]
36. Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy.
Molassiotis A; Cheng HL; Leung KT; Li YC; Wong KH; Au JSK; Sundar R; Chan A; Ng TR; Suen LKP; Chan CW; Yorke J; Lopez V
Brain Behav; 2019 Jun; 9(6):e01312. PubMed ID: 31063261
[TBL] [Abstract][Full Text] [Related]
37. Balance Deficits and Functional Disability in Cancer Survivors Exposed to Neurotoxic Cancer Treatments.
McCrary JM; Goldstein D; Trinh T; Timmins HC; Li T; Menant J; Friedlander M; Lewis CR; Hertzberg M; O'Neill S; King T; Bosco A; Harrison M; Park SB
J Natl Compr Canc Netw; 2019 Aug; 17(8):949-955. PubMed ID: 31390588
[TBL] [Abstract][Full Text] [Related]
38. Chemotherapy-induced peripheral neuropathy in African American cancer survivors: Risk factors and quality of life outcomes.
Trendowski MR; Lusk CM; Ruterbusch JJ; Seaton R; Simon MS; Greenwald MK; Harper FWK; Beebe-Dimmer JL; Schwartz AG
Cancer Med; 2021 Nov; 10(22):8151-8161. PubMed ID: 34687150
[TBL] [Abstract][Full Text] [Related]
39. Evaluating the impact of chemotherapy-induced peripheral neuropathy symptoms (CIPN-sx) on perceived ability to work in breast cancer survivors during the first year post-treatment.
Zanville NR; Nudelman KN; Smith DJ; Von Ah D; McDonald BC; Champion VL; Saykin AJ
Support Care Cancer; 2016 Nov; 24(11):4779-89. PubMed ID: 27470258
[TBL] [Abstract][Full Text] [Related]
40. Anxiety and depression mediate the association between chemotherapy-induced peripheral neuropathy and fatigue: Results from the population-based PROFILES registry.
Bonhof CS; van de Poll-Franse LV; Vissers PAJ; Wasowicz DK; Wegdam JA; Révész D; Vreugdenhil G; Mols F
Psychooncology; 2019 Sep; 28(9):1926-1933. PubMed ID: 31293046
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
